Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Joly

Showing results (201-210 of 227) with videos related to

Pageof 23
Sort By:
Journal of Advanced Research|May 17, 2022
Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of diseaseMeriem Belheouane, Britt M Hermes, Nina Van Beek, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 29, 2024
S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and VenereologyFrédéric Caux, Aikaterini Patsatsi, Meropi Karakioulaki, et al.
Haematologica|November 12, 2013
Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous LymphomasAdèle de Masson, Marie Beylot-Barry, Jean-David Bouaziz, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
Journal of Oncology|January 12, 2019
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal MelanomaClaire Mignard, Aurélie Deschamps Huvier, André Gillibert, et al.
Journal of the American Academy of Dermatology|March 15, 2008
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusDedee F Murrell, Sarah Dick, A R Ahmed, et al.
JID Innovations : Skin Science From Molecules to Population Health|January 29, 2025
Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, GreeceMeropi Karakioulaki, Patrick Dunn, Dedee F Murrell, et al.
The Journal of Investigative Dermatology|December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General PopulationMarthe Plaquevent, Florence Tétart, Laurence Fardet, et al.
Archives of Dermatology|July 18, 2012
Prognostic factors of paraneoplastic pemphigusSandy Leger, Damien Picard, Saskia Ingen-Housz-Oro, et al.
The British Journal of Dermatology|October 4, 2023
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patientsRéda Chebani, Florian Lombart, Guillaume Chaby, et al.
Pageof 23

Showing results (201-210 of 227) with videos related to

Sort By:
Pageof 23
Journal of Advanced Research|May 17, 2022
Characterization of the skin microbiota in bullous pemphigoid patients and controls reveals novel microbial indicators of diseaseMeriem Belheouane, Britt M Hermes, Nina Van Beek, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|February 29, 2024
S2k guidelines on diagnosis and treatment of linear IgA dermatosis initiated by the European Academy of Dermatology and VenereologyFrédéric Caux, Aikaterini Patsatsi, Meropi Karakioulaki, et al.
Haematologica|November 12, 2013
Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous LymphomasAdèle de Masson, Marie Beylot-Barry, Jean-David Bouaziz, et al.
Science Translational Medicine|March 8, 2013
Long-term remissions of severe pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell responseNatacha Colliou, Damien Picard, Frédérique Caillot, et al.
Journal of Oncology|January 12, 2019
Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal MelanomaClaire Mignard, Aurélie Deschamps Huvier, André Gillibert, et al.
Journal of the American Academy of Dermatology|March 15, 2008
Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusDedee F Murrell, Sarah Dick, A R Ahmed, et al.
JID Innovations : Skin Science From Molecules to Population Health|January 29, 2025
Advances in Pemphigus and Pemphigoid: A Report of the International Meeting of the Pemphigus and Pemphigoid Foundation in Thessaloniki, GreeceMeropi Karakioulaki, Patrick Dunn, Dedee F Murrell, et al.
The Journal of Investigative Dermatology|December 14, 2018
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General PopulationMarthe Plaquevent, Florence Tétart, Laurence Fardet, et al.
Archives of Dermatology|July 18, 2012
Prognostic factors of paraneoplastic pemphigusSandy Leger, Damien Picard, Saskia Ingen-Housz-Oro, et al.
The British Journal of Dermatology|October 4, 2023
Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patientsRéda Chebani, Florian Lombart, Guillaume Chaby, et al.
Pageof 23